Act on Quality of Life in Patients With aortIc Stenosis
A legfontosabb adatok
- Ki végzi
- Hospices Civils de Lyon
- Hol
- Franciaország4 helyszín, 1 országbanVálassz országot a helyszínekhez
- Azonosító
- Állapot
- Toboroz
- Résztvevők
- 240 fő, tervezett
- Kezdés
- 2024. dec. 19.
- Várható befejezés
- 2027. dec. 19.
- A vizsgálat típusa
- Megfigyeléses, 2 csoport
- A vizsgált kezelések
- Kansas City Cardiomyopathy Questionnaire (KCCQ-12) score
- A regiszteradat frissítve
- 2025. január 17.
Ki vehet részt
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.
The trial is looking for adults with severe aortic stenosis that causes symptoms and who are planned for TAVI (a valve replaced through a blood vessel). It studies their quality of life before and after the procedure.
- Életkor
- 18 Years and older
- Nem
- All
- A betegség stádiuma
- Symptomatic aortic stenosis (shortness of breath on effort, chest pain, fainting). The heart team has agreed TAVI is needed. Charlson score (a measure of other illnesses) of 5 or more.
- Biomarker vagy leletérték
- On ultrasound: valve area 1 cm² or 1 cm²/m² body surface area, or mean transvalvular aortic gradient > 40 mmHg.
A részvétel fő kizáró okai
- Refusing the TAVI procedure
- No CT scan done during the check-up before TAVI
- Unable to understand or answer quality-of-life questionnaires
- Pregnant or breast-feeding women
- Under judicial protection, guardianship or curatorship
A regiszter feltételei, szó szerint
Mind a 8 feltétel megnézéseKevesebb
Ki vehet részt
- Patients with symptomatic aortic stenosis (exertional dyspnea, angina, malaise/syncope); Indication for TAVI (valve area 1 cm² or 1 cm²/m² body surface area or mean transvalvular aortic gradient > 40 mmHg on ultrasound) validated in Heart Team; Charlson score ≥ 5; Social health care insurance affiliation
Ki nem vehet részt
- Patient refusing TAVI procedure
- CT scan not performed during the pre-TAVI assessment
- Patient unable to understand or answer quality-of-life questionnaires
- Pregnant or breast-feeding women
- Patients participating in other interventional research that may interfere with the present study with an exclusion period still in progress
- Persons under judicial protection
- Patients under guardianship, curators or safeguard of justice
Ez a vizsgálat jelenleg itt érhető el: Franciaország.
Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.
A vizsgálatról
Mit akar kideríteni a vizsgálat
Aortic stenosis (AS) is a degenerative process affecting the aortic valve that leads to sclerosis of the valve and limits its opening during cardiac contractions. The prognosis is poorly, with survival rates of only 15-50% at 5 years. AS has a major impact on quality of life, with severely limiting symptoms (dyspnea, chest pain,…) often leading to repeated hospitalizations. It is the most common valvular disease in Europe and North America, and its prevalence is increasing as the population ages. In Europe, 17% of the population is aged 65 or over; in France, this proportion will reach 30% by 2030, corresponding to 16 million people. The incidence of aortic valve sclerosis (early stage AS) is around 25% at age 65, rising to 48% after age 75. The prevalence of aortic valve disease is likely to continue to rise, given the expected evolution of the age pyramid.
A teljes eredeti leírásKevesebb
There is no medical treatment able to slow down the degenerative process of the valve, and the only treatment is aortic valve replacement when the AS becomes constricted and the patient is eligible for an intervention. Aortic valve replacement has historically been performed surgically, with open-chest surgery to remove the damaged valve and replace it with a mechanical or biological valve prosthesis. Now Transcatheter Aortic Valve Implantation (TAVI) has replaced this procedure. This involves inserting a bioprosthesis crimped into a stent via an endovascular route, i.e. without opening the thorax. Deployment of the stent crushes the native valve, leaving the functional bioprosthesis in place.
Initially developed for patients contraindicated to surgery, TAVI is now offered as a first-line treatment for patients aged 75 and over.
Inexistent before 2010, the number of TAVIs equalled the number of surgeries by 2015, and TAVIs currently account for ¾ of aortic valve procedures (unpublished data).
A vizsgálat 2 csoportja
- Poor prognosis patients
Patients will performed the Quality Of Life Questionnaire (EQ-5D-5L) and the Kansas City Cardiomyopathy Questionnaire (KCCQ-12) at baseline (day of the TAVI procedure) and 2 months post-TAVI. The CAPRI score will be calculated from the data of the pre TAVI assessment at the end of study participation (12 months) and will determine the group of the patient. The higher the score, the worse the prognosis.
Kezelés: Kansas City Cardiomyopathy Questionnaire (KCCQ-12) score
- Intermediate prognosis patients
Patients will performed the Quality Of Life Questionnaire (EQ-5D-5L) and the Kansas City Cardiomyopathy Questionnaire (KCCQ-12) at baseline (day of the TAVI procedure) and 2 months post-TAVI. The CAPRI score will be calculated from the data of the pre TAVI assessment at the end of study participation (12 months) and will determine the group of the patient. The higher the score, the worse the prognosis
Kezelés: Kansas City Cardiomyopathy Questionnaire (KCCQ-12) score
Kérdések a vizsgálat csapatának
- Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
- Megtérítik az utazási költséget?
- Megtarthatom a saját orvosomat?
- Mi történik, ha ki akarok lépni?
Contact the study team: see the registry record → Contacts and Locations
Oldal nyomtatása az orvosomnakAdatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- Act on Quality of Life in Poor Prognosis Aortic Stenosis Patients
- MI-összefoglaló
- A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 14.
- A regiszteradat frissítve
- 2025. január 17.